Targeted drugs for colon cancer with Kras gene mutation, including bevacizumab and regrafenib. 1. Bevacizumab: it is an anti-tumor angiogenesis targeted drug, used in the first-line treatment of advanced colon cancer; adverse reactions can be abdominal pain, nausea, vomiting, intestinal obstruction, blood cell drop, anemia, headache, drowsiness, arterial thrombosis, hypertension, etc.. 2. Regorafenib: it is the third-line drug for the treatment of colon cancer and an oral anti-angiogenic targeted drug; it is forbidden for patients who are allergic to this product, and used with caution for those with allergic constitution. It is necessary to find out the preferred targeted drug according to the patient’s pathological results and gene mutation in order to achieve better results. Patients with Kras mutation of colon cancer should use targeted drugs under the guidance of physician’s interview, and patients should not use drugs on their own to avoid adverse results.